TRCT
TECX

Tower Research Capital (TRC)’s Tectonic Therapeutic TECX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7K Sell
661
-253
-28% -$7.43K ﹤0.01% 3438
2026
Q1 		$28.3K Buy
914
+162
+22% +$3.99K ﹤0.01% 3227
2025
Q4 		$15.7K Sell
752
-713
-49% -$13.3K ﹤0.01% 3280
2025
Q3 		$23K Buy
1,465
+218
+17% +$4.5K ﹤0.01% 3184
2025
Q2 		$24.8K Buy
1,247
+414
+50% +$8.39K ﹤0.01% 3550
2025
Q1 		$14.8K Buy
833
+617
+286% +$20.1K ﹤0.01% 3271
2024
Q4 		$9.97K Buy
+216
New +$9.13K ﹤0.01% 3854
2024
Q3 		– Sell
-112
Closed -$1.84K – 6050
2024
Q2 		$1.84K Sell
112
-148
-57% -$2.37K ﹤0.01% 5085
2024
Q1 		$3.99K Sell
260
-55
-17% -$871 ﹤0.01% 4757
2023
Q4 		$5.14K Sell
315
-118
-27% -$2.03K ﹤0.01% 4873
2023
Q3 		$8.01K Sell
433
-563
-57% -$9.95K ﹤0.01% 4410
2023
Q2 		$11.4K Buy
996
+466
+88% +$5.27K ﹤0.01% 3984
2023
Q1 		$6K Sell
530
-732
-58% -$10.2K ﹤0.01% 4897
2022
Q4 		$11K Buy
1,262
+358
+40% +$3.15K ﹤0.01% 3893
2022
Q3 		$7K Buy
904
+38
+4% +$422 ﹤0.01% 4944
2022
Q2 		$10K Sell
866
-273
-24% -$3.22K ﹤0.01% 4496
2022
Q1 		$18K Sell
1,139
-1,091
-49% -$22.5K ﹤0.01% 3654
2021
Q4 		$103K Buy
2,230
+1,659
+291% +$95.3K ﹤0.01% 2204
2021
Q3 		$38K Buy
571
+317
+125% +$26K ﹤0.01% 3187
2021
Q2 		$27K Buy
254
+124
+95% +$14.7K ﹤0.01% 3617
2021
Q1 		$20K Sell
130
-27
-17% -$4.39K ﹤0.01% 3895
2020
Q4 		$26K Sell
157
-15
-9% -$2.67K ﹤0.01% 3704
2020
Q3 		$26K Sell
172
-305
-64% -$61.4K ﹤0.01% 3779
2020
Q2 		$100K Buy
477
+418
+708% +$86.1K ﹤0.01% 2456
2020
Q1 		$12K Sell
59
-192
-76% -$45.2K ﹤0.01% 1954
2019
Q4 		$61K Buy
251
+86
+52% +$16.6K 0.01% 1217
2019
Q3 		$28K Buy
+165
New +$37.4K ﹤0.01% 2241
2019
Q1 		– Sell
-175
Closed -$35K – 4354
2018
Q4 		$35K Buy
+175
New +$53.3K ﹤0.01% 1537

Other funds holding TECX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Tower Research Capital (TRC)'s TECX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Tectonic Therapeutic (TECX) stake by 28% in Q2 2026, selling an estimated $7.43K and leaving 661 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3438.

Tower Research Capital (TRC) first reported a position in TECX in Q4 2018 and has held it in 28 quarters since. The position peaked at $103K in Q4 2021. 122 funds tracked by Wall St. Rank hold TECX as of Q2 2026.

  • Tower Research Capital (TRC) held 661 shares of Tectonic Therapeutic worth $22.7K as of Q2 2026.
  • Tower Research Capital (TRC) sold 253 Tectonic Therapeutic shares in Q2 2026, an estimated $7.43K.
  • Tectonic Therapeutic made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3438 holding.
  • Tower Research Capital (TRC) first reported a position in Tectonic Therapeutic in Q4 2018 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Tectonic Therapeutic position peaked at $103K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.